Asunaprevir (ASV; BMS-650032) is an orally active, potent and selective hepatitis C virus (HCV) NS3 protease inhibitor (HCV NS3/4A IC50 = 0.7 nM; GBV-B NS3/4A IC50 = 21 µM, IC50 >5 µM using 11 human serine and cysteine proteases) that targets the NS3/4A protease complex with high affinity (Ki = 0.4 and 0.24 nM, using genotypes 1a (H77) and 1b (J4L6S), respectively). ASV inhibits HCV replication in cultures (IC50 = 1-4 nM/replicon genotypes 1 & 4, 67 nM-1.162 µM/replicon genotypes 2 & 3, >12 μM against a panel of other RNA viruses).
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses
Antimicrobial Agents and Chemotherapy, 57(3), 1291-1303 (2013)
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
Antimicrobial Agents and Chemotherapy, 56(10), 5387-5396 (2012)
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication
Antimicrobial Agents and Chemotherapy, 57(3), 1312-1322 (2013)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.